High Quality Content by WIKIPEDIA articles! The Oncotype DX Colon Cancer Assay, developed by Genomic Health, is a genomic test that has been clinically available for patients with newly diagnosed stage II colon cancer since January 2010. The test is a validated diagnostic assay based on an individual patient’s colon tumor expression of 12 genes, which quantifies the likelihood of recurrence in stage II colon cancer following surgery. The result from the assay is a continuous Recurrence Score® value from 0 to 100 that corresponds to a specific likelihood of colon cancer recurrence 3 years after surgery. A lower score corresponds to a lower risk of recurrence, and a higher score corresponds to a higher risk of recurrence. The Recurrence Score result provides additional information on recurrence risk beyond traditional clinical and pathological characteristics such as tumor stage (T-stage), mismatch repair (MMR) status, number of lymph nodes examined, tumor grade and lymphovascular...

В наличии:
	Books.Ru - 873 руб.	Перейти
Под заказ:
	OZON.ru - 870 руб.	Перейти

Рейтинг книги: 4 из 5, 5 голос(-ов).